Dexcom Stock Intrinsic Value – DEXCOM Reaches Record Revenue of USD 871.3 Million in Q2 FY2023, Up 25.2% Year-Over-Year

☀️Earnings Overview

On June 30th 2023, DEXCOM ($NASDAQ:DXCM) announced their Q2 FY2023 financial results, revealing a total revenue of USD 871.3 million, an increase of 25.2% from the previous year. The net income also rose 127.7% year over year, amounting to USD 115.9 million.

Analysis – Dexcom Stock Intrinsic Value

GoodWhale has conducted an analysis of DEXCOM‘s financials and determined the intrinsic value of DEXCOM share to be around $139.5 using our proprietary Valuation Line. Though this value is slightly higher than the current market price of $129.4, we still find that DEXCOM’s stock is undervalued by 7.2%. This presents an opportunity for investors to purchase the stock at a relatively low cost. We believe that DEXCOM’s strong financial strength and fast growth makes it an attractive investment opportunity. We recommend investors to consider adding the stock into their portfolio. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Dexcom. DEXCOM_Reaches_Record_Revenue_of_USD_871.3_Million_in_Q2_FY2023_Up_25.2_Year-Over-Year”>More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Dexcom. DEXCOM_Reaches_Record_Revenue_of_USD_871.3_Million_in_Q2_FY2023_Up_25.2_Year-Over-Year”>More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Dexcom. DEXCOM_Reaches_Record_Revenue_of_USD_871.3_Million_in_Q2_FY2023_Up_25.2_Year-Over-Year”>More…

Key Ratios Snapshot

Some of the financial key ratios for Dexcom are shown below. DEXCOM_Reaches_Record_Revenue_of_USD_871.3_Million_in_Q2_FY2023_Up_25.2_Year-Over-Year”>More…

Peers

The company was founded in 1999 and is headquartered in San Diego, California. DexCom has a market cap of $15.8 billion as of May 2020. The company’s competitors include Abbott Laboratories, Insulet Corp, and Medtronic PLC.

– Abbott Laboratories ($NYSE:ABT)

Abbott Laboratories is a publicly traded healthcare company with a market capitalization of $173.42 billion as of 2022. The company’s return on equity is 16.7%. Abbott Laboratories is a diversified healthcare company that develops and manufactures a wide range of products and services for the treatment of various medical conditions. The company’s product portfolio includes pharmaceuticals, diagnostics, medical devices, and nutritional products. Abbott Laboratories has a strong presence in both developed and emerging markets.

– Insulet Corp ($NASDAQ:PODD)

Insulet Corporation is a medical device company that manufactures and sells insulin delivery systems for people with diabetes. The company was founded in 2000 and is headquartered in Massachusetts, United States. Insulet Corporation has a market capitalization of 20.48 billion as of 2022 and a return on equity of 8.72%. The company’s products include the OmniPod insulin pump, the PodderPrep insulin pump starter kit, and the mylife Pods insulin pump cartridges.

– Medtronic PLC ($NYSE:MDT)

Medtronic PLC is a medical device company that focuses on providing treatments for cardiovascular diseases, diabetes, and neurological disorders, among others. As of 2022, the company has a market cap of 105.39B and a return on equity of 7.49%. Medtronic PLC is headquartered in Dublin, Ireland.

Summary

Investors are optimistic about DEXCOM‘s financial results for their Q2 FY2023. Total revenue increased by 25.2% compared to the same period of the previous year, reaching USD 871.3 million. Net income rose 127.7% year over year, ending at USD 115.9 million.

This indicates strong growth potential, and investors may find value in DEXCOM’s stock. With such positive results, DEXCOM is well-positioned to capitalize on future opportunities and continue to achieve success.